Horizon Pharma plc (HZNP) : Traders are bullish on Horizon Pharma plc (HZNP) as it has outperformed the S&P 500 by a wide margin of 10.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.35%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.28% in the last 1 week, and is up 14.69% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4.08% and the 50-Day Moving Average is 10.08%. Horizon Pharma plc is up 25.5% in the last 3-month period. Year-to-Date the stock performance stands at -10.98%.
Horizon Pharma plc (NASDAQ:HZNP): On Fridays trading session , Opening price of the stock was $19.56 with an intraday high of $19.86. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $19.24. However, the stock managed to close at $19.29, a loss of 1.68% for the day. On the previous day, the stock had closed at $19.62. The total traded volume of the day was 2,500,542 shares.
Also, In the latest statement by the brokerage house, Morgan Stanley upgrades its outlook on Horizon Pharma plc (NASDAQ:HZNP). The current rating of the shares is Equal-weight, according to the research report released by the firm. Previously, the company had a rating of Underweight. The brokerage firm maintains the price target at $24 per share. The rating by the firm was issued on July 11, 2016.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.